Press Releases

This investigator initiated study is being conducted in collaboration with the U.S. National Heart, Lung and Blood Institute (NHLBI) Jerusalem, Israel, August 21, 2017 — The first subject has been transplanted in an investigator-initiated study of Cordin™ for patients with severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS) who have no available matched donor. […]

Non-dilutive funding follows the recent closing of a $40 million round Combined financing will support further development and commercialization of NiCord®, a breakthrough designation product for blood cancers Jerusalem, Israel, July 20, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that […]

Dr. Simantov brings to the company extensive medical experience in late stage development and commercialization of cancer treatments Jerusalem, Israel and New York, New York, July 10, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that Ronit Simantov, M.D. will join […]

Financing provides strong base to complete Phase 3 clinical trial and commercialization of lead product candidate NiCord® for blood cancers Jerusalem, Israel, June 19, 2017 — Gamida Cell Ltd., a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, today announced the signing of a $40 million financing to […]

Professor Kornberg brings to Gamida Cell a celebrated expertise in scientific discovery and therapeutic development Dr. Perry brings deep R&D expertise in cell and gene therapy and decades of experience successfully guiding private and publicly traded companies Jerusalem, Israel, June 5, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment […]

NiCord-transplanted patients demonstrated improvements in time to engraftment, bacterial and non-viral grade 2-3 infection rate, and duration of hospitalization  Jerusalem, Israel, April 20, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today the publication of positive clinical outcomes from an investigator-initiated study […]

Phase 3 study of NiCord commenced last month in blood cancer patients Jerusalem, Israel, March 23, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that orphan drug designation has been granted by the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal […]

Jerusalem, Israel, February 28, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that the first patient has been transplanted in the Company’s Phase 3 study of NiCord®, in development as a cure for patients with blood cancer who do not have […]

SCD patients treated with NiCord showed rapid engraftment and were cured of disease symptoms

Jerusalem, Israel, November 21, 2016 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, today announced the appointment of Julian Adams, Ph.D. as the Company’s new chairman of the Board of Directors. “I am very pleased to welcome Julian Adams as our new chairman after […]